Deepu Madduri
Overview
Explore the profile of Deepu Madduri including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
51
Citations
4621
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Swan D, Madduri D, Hocking J
Blood Cancer J
. 2024 Nov;
14(1):206.
PMID: 39592597
The treatment of multiple myeloma has changed dramatically in recent years, with huge strides forward made in the field. Chimeric antigen receptor T-cell therapy targeting the B cell maturation antigen...
2.
Htut M, Dhakal B, Cohen A, Martin T, Berdeja J, Usmani S, et al.
Clin Lymphoma Myeloma Leuk
. 2023 Sep;
23(12):882-888.
PMID: 37716872
Background: Patients with prior allogeneic stem cell transplant (alloSCT) are typically excluded from trials of chimeric antigen receptor (CAR) T cell therapies, because their engineered cells may include allogeneic T...
3.
Lin Y, Raje N, Berdeja J, Siegel D, Jagannath S, Madduri D, et al.
Nat Med
. 2023 Aug;
29(9):2286-2294.
PMID: 37592106
Idecabtagene vicleucel (ide-cel) is a B-cell-maturation antigen (BCMA)-directed chimeric antigen receptor T cell therapy. We performed a post hoc analysis of a single-arm phase 1 multicenter study in relapsed/refractory multiple...
4.
Martin T, Madduri D, Pacaud L, Usmani S
Future Oncol
. 2023 Jul;
19(34):2297-2311.
PMID: 37497629
Cilta-cel, a BCMA-targeting chimeric antigen receptor T-cell therapy for multiple myeloma, was approved in USA on 28 February 2022, for patients with relapsed or refractory disease who have received ≥4...
5.
Berdeja J, Cohen A, Martin T, Madduri D, Pacaud L, Jagannath S
Future Oncol
. 2023 Jul;
19(18):1235-1247.
PMID: 37403937
What Is This Summary About?: This is a summary of a clinical study called CARTITUDE-1. This study tested the anti-cancer chimeric antigen receptor-T cell (CAR-T) therapy ciltacabtagene autoleucel, abbreviated as...
6.
Raghunandan S, Pauly M, Blum W, Qayed M, Dhodapkar M, Elkhalifa M, et al.
J Immunother Cancer
. 2023 May;
11(5).
PMID: 37137553
Plasmablastic lymphoma (PBL) is a rare subtype of aggressive large B-cell lymphoma, with a dismal prognosis despite aggressive therapies. New approaches are needed for those with refractory disease. PBL expresses...
7.
Martin T, Jackson C, Pacaud L, Madduri D, Jagannath S
Clin Lymphoma Myeloma Leuk
. 2022 Nov;
23(1):22-27.
PMID: 36411210
Introduction: Chimeric antigen receptor T cell (CAR-T) therapies have revolutionized the treatment paradigm for heavily pretreated B-cell malignancies such as large B-cell lymphoma. There is a major unmet need for...
8.
Cohen A, Hari P, Htut M, Berdeja J, Usmani S, Madduri D, et al.
Clin Lymphoma Myeloma Leuk
. 2022 Nov;
23(1):68-77.
PMID: 36357295
Introduction: Ciltacabtagene autoleucel (cilta-cel), a novel chimeric antigen receptor T (CAR-T) cell therapy, has demonstrated early, deep, and durable clinical responses in heavily pretreated patients with relapsed/refractory multiple myeloma (RRMM),...
9.
Martin T, Lin Y, Agha M, Cohen A, Htut M, Stewart A, et al.
Lancet Haematol
. 2022 Oct;
9(12):e897-e905.
PMID: 36215989
Background: CARTITUDE-1 is a phase 1b-2 study evaluating ciltacabtagene autoleucel (cilta-cel), a chimeric antigen receptor T cell therapy with two B-cell maturation antigen-targeting single-domain antibodies, in patients with relapsed or...
10.
Restrepo P, Bhalla S, Ghodke-Puranik Y, Aleman A, Leshchenko V, Melnekoff D, et al.
JCO Precis Oncol
. 2022 Jun;
6:e2200147.
PMID: 35704796
Purpose: Selinexor is the first selective inhibitor of nuclear export to be approved for the treatment of relapsed or refractory multiple myeloma (MM). Currently, there are no known genomic biomarkers...